Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.550
-0.010 (-0.64%)
Jun 23, 2025, 4:00 PM - Market closed
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,318,111
Market Cap
172.77M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
TLSA News
- 10 days ago - Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting - Seeking Alpha
- 10 days ago - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - GlobeNewsWire
- 10 days ago - Tiziana Life Sciences to Present at the Bio International Convention - GlobeNewsWire
- 4 weeks ago - Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - Tiziana Life Sciences Announces Purchase of Shares by Chairman - GlobeNewsWire
- 6 weeks ago - Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - GlobeNewsWire
- 7 weeks ago - Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis - GlobeNewsWire